口腔医学研究 ›› 2019, Vol. 35 ›› Issue (8): 761-765.DOI: 10.13701/j.cnki.kqyxyj.2019.08.010

• 口腔颌面外科学研究 • 上一篇    下一篇

阿司匹林/富血小板纤维蛋白复合物促进大鼠种植体周围骨缺损修复的实验研究

陈瑞1, 李风兰2*   

  1. 1. 山西医科大学口腔医学院·口腔医院 山西 太原 030001;
    2. 山西医科大学附属省人民医院口腔修复科 山西 太原 030012
  • 收稿日期:2019-01-03 出版日期:2019-08-28 发布日期:2019-08-22
  • 通讯作者: 李风兰,E-mail:uniquelfl@163.com
  • 作者简介:陈瑞(1990~ ),男,山西定襄人,硕士在读,主要从事种植体骨结合方面的研究。
  • 基金资助:
    山西省重点研发计划(编号:201703D321027-2)

Effect of Aspirin/Platelet-rich Fibrin Complex on Bone Restoration of Peri-implant Bone Defects

CHEN Rui1, LI Fenglan2*   

  1. 1. School and Hospital of Stomatology, Shanxi Medical University, Taiyuan 030001, China;
    2. Department of Prosthodontics, Affiliated People's Hospital, Shanxi Medical University, Taiyuan 030012, China
  • Received:2019-01-03 Online:2019-08-28 Published:2019-08-22

摘要: 目的:探究阿司匹林/富血小板纤维蛋白(platelet-rich fibrin,PRF)复合物修复大鼠种植体周围骨缺损的效果。方法:雄性SD大鼠30只(8周龄),12只用于制备PRF及阿司匹林/PRF复合物(阿司匹林浓度100 mg/L);18只用于制备种植体周围骨缺损模型,大鼠双侧胫骨近干骺端分别制备种植窝,在种植窝远中一侧骨壁制备1.5 mm×2.0 mm的骨缺损,植入种植体后,按骨缺损的处理情况随机分为3组:空白组:骨缺损内不做任何处理;对照组:骨缺损内植入PRF膜;实验组:骨缺损内植入阿司匹林/PRF复合物,每组各6只。植入后4、8周,每组处死3只大鼠并获取标本,制作种植体骨磨片,苦味酸-品红染色(Van Gieson,VG)染色,进行大体、组织学观察和骨计量学分析。结果:植入后4周,实验组种植体骨结合率[(57.30±6.76)%]显著高于对照组[(45.93±6.53)%]和空白组[(27.35±10.31)%](P<0.05),且对照组种植体骨结合率显著高于空白组(P<0.05);实验组新骨生成率[(24.34±6.11)%]显著高于对照组[(14.30±4.86)%]和空白组[(10.79±2.14)%](P<0.05),对照组新骨生成率与空白组比较差异无统计学意义(P>0.05)。植入后8周,实验组种植体骨结合率[(64.34±6.02)%]显著高于对照组[(52.62±6.08)%]和空白组[(54.32±6.57)%](P<0.05),对照组种植体骨结合率与空白组比较差异无统计学意义(P>0.05);3组新骨生成率[实验组:(30.16±3.58)%、对照组:(26.27±5.36)%、空白组:(25.33±4.25)%]比较差异无统计学意义(P>0.05)。结论:阿司匹林/PRF复合物可在骨愈合早期促进种植体周围骨缺损区的骨再生,缩短骨愈合时间,促进种植体骨结合。

关键词: 阿司匹林, 富血小板纤维蛋白, 种植体, 骨再生

Abstract: Objective: To evaluate the effect of Aspirin/platelet-rich fibrin (PRF) complex on repairing peri-implant bone defects in rats. Methods: A total of 30 male Sprague-Dawley rats (8 weeks of age) were used in the present study. 12 rats were used to prepare PRF and aspirin/PRF complex (100 mg/L) and 18 rats were used to prepare the peri-implant bone defects on both sides of tibia, and bone defects (1.5 mm×2.0 mm) were created along one distal bone wall of each implant sites. After implants placement, the rats were randomly divided into three groups: the bone defects in control group was left empty; the bone defects in PRF control group was implanted with PRF alone; and bone defects of aspirin/PRF complex group was implanted with aspirin/PRF complex. Three rats from each group were randomly sacrificed at 4 weeks and 8 weeks after implantation surgery. Specimens were subjected to general observation, bone histological observation, and histomorphometric analysis. Results: 4 weeks after implantation surgery, the implant bone contact rate in the aspirin/PRF complex group [(57.30±6.76)%] was significantly higher than that in the PRF control group [(45.93±6.53)%] and the control group [(27.35±10.31)%] (P<0.05), and the implant bone contact rate in the PRF control group was also significantly higher than that in the control group (P<0.05). The new bone areas percentage in the aspirin/PRF complex group [(24.34±6.11)%] was significantly higher than that in the PRF control group [(14.30±4.86)%] and the control group [(10.79±2.14)%] (P<0.05). There was no statistical difference between PRF control group and control group (P>0.05). 8 weeks after implantation surgery, the implant bone contact rate in the aspirin/PRF complex group [(64.34±6.02)%] was significantly higher than that in the PRF control group [(52.62±6.08)%] and the control group [(54.32±6.57)%] (P<0.05). There was no statistical difference between PRF control group and control group (P>0.05). In term of the new bone areas percentage, there was no statistical difference among aspirin/PRF complex group [(30.16±3.58)%], PRF control group [(26.27±5.36)%], and control group [(25.33±4.25)%] (P>0.05). Conclusions: Aspirin/PRF complex promotes bone regeneration in the bone defect area surrounding implant in the early stage of bone healing, shortens the implants and bone healing cycle, and improves the implants osseointegration.

Key words: Aspirin, platelet-rich fibrin, implant, bone regeneration